[Skip to Content]
[Skip to Content Landing]
December 23 2009

Strengthening Institutional Review Board Review of Highly Innovative Interventions in Clinical Trials

Author Affiliations

Author Affiliations: Program in Medical Ethics (Dr Lo), Department of Medicine (Drs Lo and Grady), and the Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research (Dr Lo), University of California, San Francisco.

JAMA. 2009;302(24):2697-2698. doi:10.1001/jama.2009.1917

Highly innovative approaches to disease treatment offer hope for therapeutic breakthroughs but also may cause serious unexpected adverse effects. For instance, repeated transplantation of neural stem cells resulted in multiple donor cell tumors,1 and gene transfer using retrovirus vectors caused T-cell leukemia.2 Such interventions can be considered to be highly innovative because the biological mechanisms are not fully understood, animal models do not reliably predict human effects, adverse effects cannot be minimized by starting with a low “dose,” and the interventions have never or only rarely been previously used in humans.3

First Page Preview View Large
First page PDF preview
First page PDF preview